

NZX/ASX Announcement

22 April 2025

TruScreen launches 260,000 women screening program, at Ho Chi Minh City over 5 years

- **A 5-year program to screen 260,000 women for cervical cancer in Ho Chi Minh City, Vietnam was launched on 12 April, 2025**
- **The program will use TruScreen’s unique AI-enabled, real time, non-invasive, cervical cancer screening device as its primary screening methodology.**
- **Titled ‘Community-based Cervical Cancer Screening Program’ the program will be conducted by a partnership between TruScreen Group Ltd (TruScreen), Ho Chi Minh City Public Health Association (HPHA) and distributor Gorton Health Services (GHS)**
- **The program structure was developed following the previously announced signing of an MOU by the three parties in November 2024.**
- **TruScreen was selected as the primary screening methodology for the capability of its unique, AI-enabled real time cervical cancer screening technology to assist the Government of Vietnam achieve its goal of screening 60% of women aged 30 to 54 for cervical cancer (currently only 25%). The addressable screening population of women in Vietnam aged 18 to 65 is 36 million.**

Truscreen Group Limited (NZX/ASX:TRU) (Truscreen or the Company) is pleased to announce the launching of a 5-year program to screen 260,000 women for cervical cancer in Ho Chi Minh City, Vietnam on 12 April, 2025 using TruScreen’s unique AI-enabled, real time, non-invasive, cervical cancer screening device.

The program is a partnership between TruScreen, Ho Chi Minh City Public Health Association (HPHA) and distributor Gorton Health Services (GHS). A tripartite Memorandum of Understanding (MOU) was signed in November 2024.

The formal Agreement for the program was signed on 12 April 2025 in Ho Chi Minh City by Dr Le Truong Giang (President of HPHA), Mr Tran An Bao (CEO GHS Vietnam) and Mr Tony Ho (Chair, TruScreen).



Mr Tony Ho, Chair TruScreen, Dr Le Truong Giang, President HPHA and Mr Tran An Bao, CEO GHS

The keynote speech inaugurating the program was delivered by Prof. Dr. Nguyen Chan Hung, President of Vietnam Cancer Association to an audience including representatives of the Ho Chi Minh City Public Health Association, the Ho Chi Minh City Centre for Disease Control, The Vietnam Cancer Association, The Ho Chi Minh City Health Centres Reproductive Health Department and the Australian Consulate in Ho Chi Minh City.



Representatives of the District Health Centres, the Australian Trade Commission, the HCMC CDC, HCMC HPHA, Vietnam Cancer Assoc, GHS and TruScreen

The Government of Vietnam has implemented the National Action Plan on Cervical Cancer Prevention (2016-2025), with the goal of screening 60% of women aged 30 to 54 for cervical cancer. Currently, about 25% of Vietnamese women have ever been screened for this condition. The primary challenge is that many women are unaware of the risk of cervical cancer and the benefits and importance of early screening for cervical cancer detection.

The objectives of the Community-based Cervical Cancer Screening Program are:

- Promote awareness, attitudes, and preventive practices for cervical cancer among women
- Collect large-scale epidemiological data on cervical cancer and pre-cancer in Vietnam
- Develop a proactive, community-based cervical cancer screening model for future nationwide implementation
- Contribute to the citywide elimination of cervical cancer in line with WHO guidelines and Vietnam Ministry of Health

TruScreen will be the screening methodology of choice for the program. TruScreen was selected for its unique, AI-enabled, real time, non-invasive cervical cancer screening technology, requiring no cytology or other laboratory infrastructure. TruScreen's portability, ease of use and accurate AI enabled algorithm delivering real time results align with the programs objective for early detection in large populations.

Ho Chi Minh City Public Health Association (HPHA) will organize and manage the overall project's implementation, including promotion of the program, recruitment of social workers, securing local government approvals and agreements with community health centres and hospitals. HPHA is a socio-professional organization established in 2007 by the Peoples Committee of Ho Chi Minh City and is charged with communication and education on community health management as well as implementing programs, projects and community health events in Ho Chi Minh City.

Gorton Health Services Company Limited (GHS), the authorized distributor of TruScreen in Vietnam, will coordinate between TruScreen and HPHA, as well as import, distribute and install the TruScreen products (device and SUS) to screening locations, provide training and support, and collect, compile, and report screening data for analysis.

Program delivery

- Social workers will be trained on the details of cervical cancer screening and visit their local community door-to-door to educate women on cervical cancer risk and register participants for the program. The preferential target population for screening will be women 30 to 49 who have had sexual intercourse and present as high risk due to multiple children, HPV infection, living with HIV, smoking (etc)
- Screening will take place at the gynaecology clinics of the District Health Centres and high-tech private clinics. Three major hospitals will provide technical support: Tu Du Hospital, Hung Vuong Hospital, and Ung Buou Hospital.
- Media support will be provided by the Ho Chi Minh City Women's Union.
- The program will begin in Ho Chi Minh City, with plans for gradual expansion to other provinces across Vietnam.

TruScreen CEO, Marty Dillon commented: *"This program with its target of Screening 260,000 women may save the lives of over 2,600 mothers, daughters, sisters, wives and friends. TruScreen was identified as the ideal screening technology for its unique ability to provide accurate, real time results without the need for any expensive laboratory infrastructure and its portability which allows for the program to 'go to the community', increasing screening uptake amongst the women of Ho Chi Minh City."*

"This HPHA screening program will also serve as an important reference site for neighbouring countries who may be considering similar large scale screening program to improve Women's Health."

This announcement has been approved by the Board.

Ends

For more information, visit www.truscreen.com or contact:

Martin Dillon

Chief Executive Officer

martindillon@truscreen.com

Guy Robertson

Chief Financial Officer

guyrobertson@truscreen.com

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low level of optical and electrical stimuli.

TruScreen's cervical screening technology enables cervical screening, negating sampling and processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly, specialised personnel and supporting laboratory infrastructure.

The TruScreen device, TruScreen Ultra®, is registered as a primary screening device for cervical cancer screening.

The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines, among others and has distributors in 29 countries. In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China.

TruScreen technology has been recognised in CSCCP's (Chinese Society for Colposcopy and Cervical Pathology) China Cervical Cancer Screening Management Guideline.

TruScreen has been recognised in a China Blue Paper "Cervical Cancer Three Stage Standardized Prevent and Treatment" published on 28 April 2023.

In Dec 2023 TruScreen technology was added to the Vietnam Ministry of Health approved National Technical List, for use in Vietnam's public and private healthcare sectors and in 2024 was added to the Russian guidelines for the screening of cervical cancer.

In financial year 2024 alone, over 200,000* examinations were performed with the TruScreen device. To date, over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen's vision is "A world without the cervical cancer".

To learn more, please visit: www.truscreen.com/.

**Based on Single Use Sensor sales.*

Glossary:

Pap smear (the Papanicolaou smear) test involves gathering a sample of cells from the cervix, with a special brush. The sample is placed on a glass slide or in a bottle containing a solution to preserve the cells. Then it is sent to a laboratory for a pathologist to examine under a microscope. <https://www.cancer.net/navigating-cancer-care/diagnosing-cancer/tests-and-procedures/pap-test>

LBC (the liquid-based cytology) test, transfers a thin layer of cells, collected with a brush from the cervix, onto a slide after removing blood or mucus from the sample. The sample is preserved so other tests can be done at the same time, such as the human papillomavirus (HPV) test <https://www.cancer.net/cancer-types/cervical-cancer/diagnosis>

HPV (human papilloma virus) test is done on a sample of cells removed from the cervix, the same sample used for the Pap test or LBC. This sample is tested for the strains of HPV most commonly linked to cervical cancer. HPV testing may be done by itself or combined with a Pap test and/or LBC. This test may also be done on a sample of cells which a person can collect on their own. <https://www.cancer.net/cancer-types/cervical-cancer/screening-and-prevention>

Sensitivity and specificity mathematically describe the accuracy of a test which reports the presence or absence of a condition. If individuals who have the condition are considered "positive" and those who don't are considered "negative", then sensitivity is a measure of how well a test can identify true positives and specificity is a measure of how well a test can identify true negatives:

- **Sensitivity** (true positive rate) is the probability of a positive test result, [conditioned](#) on the individual truly being positive.
- **Specificity** (true negative rate) is the probability of a negative test result, conditioned on the individual truly being negative ([Sensitivity and specificity – Wikipedia](#)).

For more information about the cervical cancer and cervical cancer screening in New Zealand and Australia, please see useful links:

New Zealand: [National Cervical Screening Programme | National Screening Unit \(nsu.govt.nz\)](#)

Australia: [Cervical cancer | Causes, Symptoms & Treatments | Cancer Council](#)